Financial Highlights
During the period, the Company recorded an operating revenue of RMB 301.2 million, representing an increase of 33.9% period-over-period. The increase in revenue was mainly attributable to:
(i) continued commercialization and expanded market share gains among transcatheter aortic valve replacement ("TAVR") products throughout China;
(ii) the surged sales volume of coil products as a direct result of winning bids in volume-based procurements across multiple provinces;
(iii) The rapid market penetration of our ischemic products, characterized by their differentiated design features such as the Syphonet Stent Retriever and Fastunnel Delivery Balloon Catheter; and
(iv) the successful launch of DCwire Micro Guidewire which quickly gained market recognition for its outstanding performance.
During the period, the Company recorded a gross profit of RMB 218.9 million, representing an increase of 26.5% period-over-period. Gross profit margin remained robust at 72.7%. Expense ratios decreased notably company-wide as a result of larger economic scale and improved operational efficiency with selling and distribution, administrative, and R&D expense ratios decreasing by 26.2, 7.0, and 42.8 percentage points, respectively.
Loss for the first half of 2024 was RMB 71.3 million, a 66.4% improvement when compared to RMB 212.3 in the prior year ...
